An evidence-based cost-effectiveness model on methods of prevention of posttraumatic venous thromboembolism - Editorial comment

被引：0
|
作者：
Owings, JT [1 ]
机构：
[1] Univ Calif Davis, Sacramento, CA 95817 USA
来源：
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE | 2000年 / 49卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：1064 / 1064
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK
    Folkerts, Kerstin
    Broughton, Julie
    Sheikh, Usman
    Mckaig, Sasha
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (11) : 1179 - 1191
  • [42] Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review
    Al Mukdad, Mohammad
    Al-Badriyeh, Daoud
    Elewa, Hazem Fathy
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2019, 25
  • [43] COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM IN TOTAL HIP AND KNEE REPLACEMENT IN PORTUGAL
    Mateus, C.
    Wolowacz, S.
    Pereira, J. A.
    VALUE IN HEALTH, 2009, 12 (03) : A148 - A148
  • [44] A Canadian Study of the Cost-Effectiveness of Apixaban Compared With Enoxaparin for Post-Surgical Venous Thromboembolism Prevention
    Revankar, Nikhil
    Patterson, John
    Kadambi, Ananth
    Raymond, Vincent
    El-Hadi, Wissam
    POSTGRADUATE MEDICINE, 2013, 125 (04) : 141 - 153
  • [45] Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence
    Lanitis, Tereza
    Leipold, Robert
    Hamilton, Melissa
    Rublee, Dale
    Quon, Peter
    Browne, Chantelle
    Cohen, Alexander T.
    CLINICAL THERAPEUTICS, 2016, 38 (03) : 478 - 493
  • [46] PREVENTION OF VENOUS THROMBOEMBOLISM AFTER GENERAL-SURGERY - COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE APPROACHES TO PROPHYLAXIS
    OSTER, G
    TUDEN, RL
    COLDITZ, GA
    AMERICAN JOURNAL OF MEDICINE, 1987, 82 (05): : 889 - 899
  • [47] Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden - Cost-effectiveness analysis
    Marchetti, M
    Pistorio, A
    Barosi, G
    THROMBOSIS AND HAEMOSTASIS, 2000, 84 (05) : 752 - 757
  • [48] Exploring the cost-effectiveness of HPV vaccination in Vietnam: Insights for evidence-based cervical cancer prevention policy
    Kim, Jane J.
    Kobus, Katie E.
    Diaz, Mireia
    O'Shea, Meredith
    Van Minh, Hoang
    Goldie, Sue J.
    VACCINE, 2008, 26 (32) : 4015 - 4024
  • [49] A decision-tree model to estimate the impact on cost-effectiveness of a venous thromboembolism prophylaxis guideline
    Ferrando, A.
    Pagano, E.
    Scaglione, L.
    Petrinco, M.
    Gregori, D.
    Ciccone, G.
    QUALITY & SAFETY IN HEALTH CARE, 2009, 18 (04): : 309 - 313
  • [50] A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines
    Mason, FNMJ
    Eccles, M
    Freemantle, N
    Drummond, M
    HEALTH POLICY, 1999, 47 (01) : 37 - 52
12345